Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Mazdutide

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 48
  • Status: Phase 3 Clinical
  • What does this mean?
  • Molecular Structure: Dual GLP-1/Glucagon Receptor Agonist

About Mazdutide

Investigational GLP-1/glucagon receptor dual agonist (IBI362) by Innovent Biologics. Phase 3 trials demonstrate clinically significant weight loss and improved lipid profiles. Represents next-generation metabolic peptide architecture beyond single GLP-1 agonism.

Clinical Focus

GLP-1/Glucagon Dual Agonism & Metabolic Efficiency

Archival Aliases

IBI362, GLP-1/GCG Dual

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight Dual GLP-1/Glucagon Receptor Agonist
Primary Pathway Metabolic & Weight Loss
Research Phase Phase 3 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] clinicaltrials.gov

Data Verified: 2026-04-10

Synergistic Matrix